Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study

Kristine A. Frerichs, MD, Monique C. Minnema, Mark-David Levin, MD PhD, Annemiek Broyl, MD PhD, Gerard Bos, MD PhD, Marie José Kersten, MD PhD, Tuna Mutis, Christie P.M. Verkleij, MD, Patricia W.C. Bosman, MSc, Saskia K. Klein, MD PhD, Sonja Zweegman, MD PhD, Pieter Sonneveld, Niels W. C. J. Van De Donk, MD PhD

Blood (2019) 134 (Supplement_1): 1826.

https://doi.org/10.1182/blood-2019-123383

Published: 2019

Journal Articles

Targeting the Plasma Cell Specific Purine Metabolic Enzyme, AMPD1, Induces Multiple Myeloma Cell Death Accompanying NAD Depletion

Yawara Kawano, MD PhD, Takayuki Sasano, Saki Kushima, Yuki Inada, Nao Nishimura, MD, Hiroyuki Hata, MD PhD, Masao Matsuoka, MD PhD

Blood (2019) 134 (Supplement_1): 3097.

https://doi.org/10.1182/blood-2019-125756

Published: 2019

Journal Articles

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Svetlana Trestman, MD, Chezi Ganzel, MD, Shai Levi, MSc, Moshe E. Gatt, MD, Noa Lavi, MD, Iuliana Vaxman, MDBA, Ory Rouvio, MD, Hila Magen, MD, Netanel A Horowitz, MD, Merav Leiba, MD, Tamar Tadmor, MD, Katrin Herzog Tzarfati, MD, Celia Surio, MD, Shay Yeganeh, MD, Nagib Deli, MD, Irit Avivi, MD, Cohen Yael, Dr.

Blood (2019) 134 (Supplement_1): 3180.

https://doi.org/10.1182/blood-2019-128325

Published: 2019

Journal Articles

Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)

Takeshi Yoroidaka, MD, Hiroyuki Takamatsu, MD PhD, Takeshi Yamashita, MD, Ryoichi Murata, MD, Kyoko Yoshihara, MD PhD, Satoshi Yoshihara, MD PhD, Mikio Ueda, MD PhD, Shinji Nakao, MD PhD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 3130.

https://doi.org/10.1182/blood-2019-126552

Published: 2019

Journal Articles

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Dennis Cooper, MD, Deepu Madduri, MD, Suzanne Lentzsch, MD PhD, Sundar Jagannath, Jingjin Li, PhD, Anita Boyapati, PhD, Lieve Adriaens, PharmD, Dhruti Chokshi, BS, Min Zhu, PhD, Israel Lowy, MD PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Manish Sharma, MD, Maria Karasarides, PhD, David Sternberg, MD PhD

Blood (2019) 134 (Supplement_1): 3176.

https://doi.org/10.1182/blood-2019-126818

Published: 2019

Journal Articles

Efficacy and Safety of CAR-T Therapy with Safety Switch Targeting Bcma for Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Clinical Study

Weijun Fu, Sr., MD PhD, Juan Du, MD, Hua Jiang, MD, Zhi CHENG, MD, Runhong Wei, MD, Kang Yu, MD, Songfu Jiang, MD, Feng He, Hongliang Fang, PhD, Yarong Liu, PhD, Pin Wang

Blood (2019) 134 (Supplement_1): 3154.

https://doi.org/10.1182/blood-2019-127608

Published: 2019

Journal Articles

Durable Remission Achieved from Bcma-Directed CAR-T Therapy Against Relapsed or Refractory Multiple Myeloma

Yarong Liu, PhD, Zhi Chen, MD, Hongliang Fang, PhD, Runhong Wei, MD, Kang Yu, MD, Songfu Jiang, PhD, Weijun Fu, MDPhD, Hua Jiang, MD, Juan Du, PhD MD, Feng He, Ronglin Xie, Jing Chen, Baofeng Wei, Jin Tao, Pin Wang

Blood (2018) 132 (Supplement 1): 956.

https://doi.org/10.1182/blood-2018-99-112786

Published: 2018

Journal Articles

HIV-Related Primary Diffuse Large B Cell Lymphoma of the Appendix. What Can We Learn?

Michelle Janania Martinez, MD, Adolfo E Diaz, MD, Cynthia Forker, MD

Blood (2018) 132 (Supplement 1): 5423.

https://doi.org/10.1182/blood-2018-99-119865

Published: 2018

Journal Articles

The Purine Metabolic Enzyme AMPD1 Is a Novel Therapeutic Target for Multiple Myeloma

Yawara Kawano, MD PhD, Yuki Inada, Takayuki Sasano, Nao Nishimura, MD, Hiroyuki Hata, MD PhD, Masao Matsuoka, MD PhD

Blood (2018) 132 (Supplement 1): 5614.

https://doi.org/10.1182/blood-2018-99-118603

Published: 2018

Journal Articles

Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant

Enrique M. Ocio, MD, Paula Rodriguez Otero, MD, Sara Bringhen, MD, Stefania Oliva, Axel Nogai, MD, Michel Attal, MD PhD, Philippe Moreau, Dheepak Kanagavel, Thomas F Fitzmaurice, PhD, Junlong Wu, Joaquin Martinez Lopez, MD PhD

Blood (2018) 132 (Supplement 1): 595.

https://doi.org/10.1182/blood-2018-99-111244

Published: 2018

Journal Articles

Matrix Metalloproteinase and Tissue Inhibitor of Metalloproteinases Is Associated with Multiple Myeloma Progression, Prognosis and Extramedullary Plasmacytoma

Blood (2018) 132 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2018-99-113355

Published: 2018

Journal Articles

Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial

Blood (2017) 130 (Supplement 1): 905.

https://doi.org/10.1182/blood.V130.Suppl_1.905.905

Published: 2017

Journal Articles

Effective Treatment of Relapsed/Refractory Multiple Myeloma Including Extramedullary Involvement By BCMA-Specific Chimeric Antigen Receptor-Modified T Cells

Jian-Qing Mi, MD PhD, Xiaohu (Frank) Fan, PhD, Jie Xu, PhDMD, Yuanfang Liu, MD PhD, Yan Zhuang, PhD, Shuangshuang Yang, Wu Zhang, PhD, Bing Chen, MD PhD, Yueying Wang, PhD, Xiangqin Weng, Junmin Li, Weijun Fu, MD, Hua Jiang, MD, Li Zhu, Zhu Chen, PhD, Sai-Juan Chen, PhD, Jian Hou, PhD MD

Blood (2017) 130 (Supplement 1): 3115.

https://doi.org/10.1182/blood.V130.Suppl_1.3115.3115

Published: 2017

Journal Articles

Incidence and Outcome of Soft-Tissue Plasmacytomas in Patients with Multiple Myeloma before and after the Introduction of Novel Drugs

Raquel Jiménez, MD, Laura Rosinol, MD PhD, Maria Teresa Cibeira, MD PhD, Carlos Fernández De Larrea, MD PhD, Esther Blade, Natalia Tovar, MD PhD, Joan Bladé, MD PhD

Blood (2017) 130 (Supplement 1): 3140.

https://doi.org/10.1182/blood.V130.Suppl_1.3140.3140

Published: 2017

Journal Articles

Histopathological Features of Bone Marrow and Extramedullary Sites in Patients with Multiple Myeloma

Maiia V. Firsova, Larisa P. Mendeleeva, MD PhD Prof, Alla M. Kovrigina, MD PhD, Olga S. Pokrovskaya, MD PhD, Natalia L. Deineko, MD, Maxim V. Solovev, MD, Maria V. Nareyko, MD, Larisa A. Kuzmina, MD PhD, Eduard G. Gemdzhian, PhD, Valeriy G. Savchenko

Blood (2017) 130 (Supplement 1): 5358.

https://doi.org/10.1182/blood.V130.Suppl_1.5358.5358

Published: 2017

Journal Articles

Frequency and Outcome of Clinically Signficant Incidental Findings in Plasma Cell Dyscrasias Patients Undergoing Whole Body FDG PET-CT Scan

Ehsan Shabbir, MD, Sarah L Mott, Lindsay Dozeman, Umar Farooq, MD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Guido J. Tricot, MD PhD

Blood (2017) 130 (Supplement 1): 5376.

https://doi.org/10.1182/blood.V130.Suppl_1.5376.5376

Published: 2017

Journal Articles

Clinical Features and Outcomes of Plasmacytoma in the United States: Analysis Using the National Cancer Data Base

Gaurav Goyal, MBBS, Wilson I Gonsalves, MD, Ronald S. Go, MD, Shaji Kumar, MD

Blood (2016) 128 (22): 3249.

https://doi.org/10.1182/blood.V128.22.3249.3249

Published: 2016

Journal Articles

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

Ashraf Z Badros, MD, Elizabeth Hyjek, MD PhD, Ning Ma, Alexander M. Lesokhin, MD, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Emily Lederer, RN, Sunita Philip, MBBS, Patricia Lesho, Ashlee Johnson, Cameron Dell, Olga Goloubeva, PhD, Zeba Singh, MD

Blood (2016) 128 (22): 490.

https://doi.org/10.1182/blood.V128.22.490.490

Published: 2016

Journal Articles

Efficacy of Novel Agents on Soft-Tissue Plasmacytomas in Patients with Relapsed Multiple Myeloma

Raquel Jiménez-Segura, PhD, Carlos Fernández De Larrea, MD PhD, Maite Cibeira, MD PhD, Natalia Tovar, Esther Bladé, Ignacio Isola, MD PhD, Joan Bladé, Laura Rosiñol

Blood (2016) 128 (22): 5709.

https://doi.org/10.1182/blood.V128.22.5709.5709

Published: 2016

Journal Articles

BRAF V600E Targetable Mutation in Relapsed/Refractory Multiple Myeloma (R/R MM) Patients: A High Incidence in R/R MM Detected Using Cell Sorting Screening

Alina Danu, MD, Sophie Cotteret, PhD, Ludovic Lacroix, Véronique Saada, PharmD, Véronique Vergé, MD, Nathalie Auger, Julien Lazarovici, MD, Edith Carton, Jonathan Farhi, Khalil Saleh, MD, David Ghez, PhD MD, Claude Chahine, MD, Jean-Marie Michot, MD, Vincent Ribrag, MD

Blood (2016) 128 (22): 5638.

https://doi.org/10.1182/blood.V128.22.5638.5638

Published: 2016

NARROW

Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study

Targeting the Plasma Cell Specific Purine Metabolic Enzyme, AMPD1, Induces Multiple Myeloma Cell Death Accompanying NAD Depletion

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Efficacy and Safety of CAR-T Therapy with Safety Switch Targeting Bcma for Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Clinical Study

Durable Remission Achieved from Bcma-Directed CAR-T Therapy Against Relapsed or Refractory Multiple Myeloma

HIV-Related Primary Diffuse Large B Cell Lymphoma of the Appendix. What Can We Learn?

The Purine Metabolic Enzyme AMPD1 Is a Novel Therapeutic Target for Multiple Myeloma

Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant

Matrix Metalloproteinase and Tissue Inhibitor of Metalloproteinases Is Associated with Multiple Myeloma Progression, Prognosis and Extramedullary Plasmacytoma

Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial

Effective Treatment of Relapsed/Refractory Multiple Myeloma Including Extramedullary Involvement By BCMA-Specific Chimeric Antigen Receptor-Modified T Cells

Incidence and Outcome of Soft-Tissue Plasmacytomas in Patients with Multiple Myeloma before and after the Introduction of Novel Drugs

Histopathological Features of Bone Marrow and Extramedullary Sites in Patients with Multiple Myeloma

Frequency and Outcome of Clinically Signficant Incidental Findings in Plasma Cell Dyscrasias Patients Undergoing Whole Body FDG PET-CT Scan

Clinical Features and Outcomes of Plasmacytoma in the United States: Analysis Using the National Cancer Data Base

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

Efficacy of Novel Agents on Soft-Tissue Plasmacytomas in Patients with Relapsed Multiple Myeloma

BRAF V600E Targetable Mutation in Relapsed/Refractory Multiple Myeloma (R/R MM) Patients: A High Incidence in R/R MM Detected Using Cell Sorting Screening

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only